AlphAIAlphAI — Financial news for AI agents
tradingview.com

iBio, Inc. Stock 12‑Month Price Target Cut to $5.53, Implies 447% Upside

Analysts cut iBio Inc.'s 12-month price target from $5.69 to $5.53, with forecasts ranging from $4.2 to $7. The new target implies 447% upside from the Oct. 7 closing price. All 8 analysts maintain a 'Buy' rating.

Original reporting
tradingview.com
Published Oct 8, 2026, 4:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 4:21 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
iBio, Inc. Stock 12‑Month Price Target Cut to $5.53, Implies 447% Upside — source image
Source · tradingview.com
Decision brief

The 30-second read

Low
01

Why it matters

The modest target reduction may temper short‑term enthusiasm, but the still‑large upside keeps the stock on watchlists.

02

Market read

Analyst target adjustment provides a small new data point for traders, but limited overall market relevance.

03

What to watch

Liquidity constraints and the company's cash runway may limit the practical upside despite the high percentage.

Relevance 5/10Novelty 5/10Timing: today

Background

iBio is a micro‑cap biotech company whose shares are closely watched by specialist investors. Analyst price‑target updates are a common source of short‑term trading ideas.

Market effects

Sector

May slightly lift sentiment in the small‑cap biotech sector as analysts highlight upside potential.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Minimal global impact.

Counterpoint

What could challenge this read

The price‑target cut could signal underlying concerns not reflected in the upside estimate.

Key entities

  • company
    iBio, Inc.

    US‑listed biotech firm (NASDAQ: IBI).

Read at source← All news

Related articles

$IBIOMed

Presented additional preclinical data supporting IBIO-610’s potential to drive fat selective weight loss in combination with GLP-1 therapy

iBio, Inc. (IBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate Update Presented additional preclinical data supporting IBIO-610’s potential to drive fat selective weight loss in combination with GLP-1 therapy Completed dosing in the single ascending dose p

SEC EDGAR 8-K
$IBIOMed

In an eight-week obese NHP study, lean mass made up 6% of weight lost with IBIO-610, an Activin E antibody, plus semaglutide, versus 22% with semaglutide alone

iBio, Inc. (IBIO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 Therapy In an eight-week obese NHP study, lean mass made up 6% of weight lost with IBIO-610, an Activin E antibody, plus semaglutide, vers

SEC EDGAR 8-K
$IBIOMedAI 8/10

iBio reports muscle preservation data for obesity drug candidate

iBio Inc. (IBIO) reported preclinical data showing its obesity drug candidate, IBIO-610, combined with semaglutide, preserved lean mass and increased fat loss in obese non-human primates. The study found a 97% reduction in Activin E levels and a 33.2-day half-life for the antibody. The company plans to start human trials in 2027. According to the CEO, the data suggests potential for improved weight loss quality. iBio is a clinical-stage biotech firm focusing on obesity and related diseases.

investing.com
$IBIOMed

iBio, Inc. (IBIO): Results of Operations and Financial Condition

iBio, Inc. (IBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update SAN DIEGO, August 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic an

SEC EDGAR 8-K
$IBIOMedAI 9/10

iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity

iBio (NASDAQ: IBIO) said it dosed the first participant in a Phase 1 trial of IBIO-600, its first obesity/cardiometabolic program to enter human testing. The randomized, double-blind, placebo-controlled single-ascending-dose study will assess safety, tolerability, PK/PD and body-composition effects in ~32 adults with overweight/obesity, with completion expected in 2H 2027.

manilatimes.net